This invention relates to controlling the transfer of medical fluids and, more particularly, to limiting the transmission of gas bubbles within the medical fluids.
Many types of medical fluids are routinely used to treat patients, including chemotherapy drugs, antibiotics, immunosuppressive drugs, antiviral drugs, hydrating fluids, nourishing fluids, anticoagulants, pain management drugs, contrast fluids for medical imaging, etc. All of these fluids, in turn, come in many different varieties with advantages and disadvantages for various types of diseases, conditions, injuries, or therapies. Moreover, particular patients require optimized dosages, concentrations, and combinations of these drugs or other medical fluids to address their specific medical needs. As a result, medical facilities are required to provide many different types of customized medical fluids on a continual basis to meet individual patient needs. In meeting these needs, a small amount of air is often present in the medical fluids that are prepared.
Systems and methods disclosed herein address various challenges related to medical fluid transfer systems and the presence of air in medical fluids.
In some embodiments, a bubble trap for use in a medical fluid line is disclosed.
In some embodiments, a medical fluid bubble trap system is disclosed. The system can include a bubble trap configured to be in fluid communication with at least one of a source container and a destination container. The bubble trap can be configured to trap gas that flows into the bubble trap.
In some embodiments, a medical fluid bubble trap system is disclosed. The system can include a source container and a fluid transfer module comprising a bubble trap and a destination container. The bubble trap can be configured to trap gas that flows into the bubble trap.
In some embodiments, a medical fluid transfer module comprising a bubble trap configured to trap gas in a chamber is disclosed.
In some embodiments, an electronic medical fluid transfer device comprising a bubble trap configured to trap gas in a chamber is disclosed.
In some embodiments, an inline bubble trap device is configured to be in fluid communication with a medical fluid line to inhibit a flow of gas from an inlet to an outlet. The bubble trap device can comprise an inlet comprising an inlet opening having an inlet opening center axis, an outlet comprising an outlet opening having an outlet opening center axis, and a chamber. The inlet opening center axis and the outlet opening center axis can be different from one another such that the inlet opening is misaligned from the outlet opening. In some embodiments, the misalignment of the inlet opening from the outlet opening breaks up a fluid path from the inlet opening to the outlet opening. The chamber can be configured to trap gas that flows into the bubble trap. The chamber can be located between the inlet and the outlet.
In some embodiments, an outlet can comprise an outlet projection. The outlet projection can comprise an outlet opening and a channel in fluid communication with the outlet. The outlet projection can extend into the chamber away from an inner surface of the chamber. The outlet opening of the outlet projection can be positioned near or at the center of the chamber. The outlet opening of the outlet projection can be positioned on a side of the outlet projection.
In some embodiments, an inlet comprises an inlet projection. The inlet projection can comprise an inlet opening and a channel in fluid communication with the inlet. The inlet projection can extend into the chamber away from an inner surface of the chamber. The inlet opening can be positioned near or at the center of the chamber. The inlet opening can be positioned on a side of the inlet projection.
In some embodiments, an inlet projection and an outlet projection can extend past each other such that inlet opening is positioned closer to an outlet than the outlet opening.
In some embodiments, every flow path from an inlet opening to an outlet opening includes a bend. An inlet and an outlet can be on opposite ends of a chamber.
In some embodiments, a bubble trap can include a resilient housing at least partially defining a chamber with a rest volume. The housing can be configured to at least partially collapse when subjected to a vacuum so as to reduce the volume of the chamber and configured to return to the rest volume when the vacuum is removed.
In some embodiments, a medical fluid transfer system is configured to trap air during the transfer of medical fluids. The medical fluid transfer system can comprise a fluid transfer device configured to transfer fluid from a fluid source to a fluid destination and an inline bubble trap, as described herein. The inline bubble trap can comprise a female luer end and a male luer end. The bubble trap can be configured to be in fluid communication with at least one of the fluid transfer device, a fluid source, and a fluid destination. The bubble trap can be configured to inhibit a transfer of gas from the fluid source, through the outlet of the bubble trap, and into the fluid destination. The bubble trap can be in fluid communication with the fluid source. The bubble trap can be in fluid communication with the fluid destination. The female luer end can be adjacent to the outlet. The male luer end can be adjacent to the inlet.
In some embodiments, a method of transferring fluids from a source container to a destination container can comprise the step of obtaining a fluid transfer module configured to inhibit a transfer of gas from the source container to the destination container. The fluid transfer module can comprise an inline bubble trap. The bubble trap can comprise a chamber, an inlet opening having an inlet center axis, and an outlet opening having an outlet center axis different from the inlet center axis such that the inlet opening is misaligned from the outlet opening. The method of transferring fluids can further comprise the steps of ensuring the fluid transfer module is in fluid communication with the source container and the destination container and transferring fluid from the source container, through the fluid transfer module, and into the destination container. The method can further comprise the step of initiating a vacuum in the destination container and the fluid transfer module such that a volume defined by the chamber of the fluid transfer module is reduced prior to initiating the transferring step. The inlet opening being misaligned from the outlet opening can break up a fluid path from the inlet opening to the outlet opening. The fluid transfer module can further comprise an outlet projection having the outlet opening and a channel in fluid communication with the outlet. The outlet projection can extend into the chamber away from an inner surface of the chamber. The outlet opening of the outlet projection can be positioned on a side of the outlet projection. The fluid transfer module can further comprise an inlet projection having the inlet opening and a channel in fluid communication with the inlet. The inlet projection can extend into the chamber away from an inner surface of the chamber. The inlet opening can be positioned on a side of the inlet projection. The method can further comprise disconnecting the fluid transfer module from the source container and the destination container.
In some embodiments, an inline bubble trap device is configured to be in fluid communication with a medical fluid line to inhibit a flow of gas from an inlet to an outlet. The bubble trap device can comprise a chamber comprising an inner surface and an outer surface, an inlet comprising an inlet projection extending into the chamber, the inlet projection having an inlet channel and an inlet opening being displaced away from the inner surface of the chamber, an outlet comprising an outlet projection extending into the chamber, the outlet projection having an outlet channel and an outlet opening being displaced away from the inner surface of the chamber. The inlet opening and the outlet opening can be oriented away from each other such that fluid moving between the openings need take an indirect path. At least one of the inlet and the outlet channels can comprise a curve that misaligns the inlet opening from the outlet opening and breaks up a fluid path from the inlet opening to the outlet opening through the chamber. The chamber can be configured to trap gas that flows into the bubble trap. The chamber can be collapsible. The outlet opening of the outlet projection can be positioned near or at the center of the chamber. The inlet opening can be positioned near or at the center of the chamber. The inlet projection and the outlet projection can project past each other within the chamber.
In some embodiments, a patient source bag is for use with a medical fluid infusion pump. The patient source bag can comprise a chamber, an outlet comprising an outlet region in fluid communication with the chamber, and a barrier defining an air collection region in fluid communication with the outlet. The barrier can be configured to maintain air within the air collection region. The barrier can be configured inhibit the transfer of gas through the outlet region. The air collection region can be located outside a continuous fluid flow path between the chamber and the outlet region. The air collection region can be spaced apart from the outlet. The outlet can be located on an upper region of the chamber. The outlet can be configured to permit the passage of fluid into and out of the chamber. The patient source bag can further comprise a port configured to permit the removal of air from the chamber. The patient source bag can further comprise at least one access port. The access port can be a closeable female luer connector. The access port can be a closeable male luer connector. The patient source bag can further comprise a bubble trap outside the chamber an in fluid communication with the chamber.
Embodiments will now be described with reference to the following drawings, which are provided by way of example, and not limitation. Like reference numerals indicate identical or functionally similar elements.
i is a front perspective view of an example of an electromechanical system for transferring medical fluid.
i is a rear view of an example of a fluid transfer device.
i is a front perspective view of the electromechanical system for transferring medical fluid of
i is a magnified partial front view of the electromechanical system of
ii is a front perspective view of an example of an electromechanical system for transferring medical fluid according to another embodiment.
ii is a rear view of an example of a fluid transfer device according to another embodiment.
ii is a front perspective view of the electromechanical system for transferring medical fluid of
ii is a magnified partial front view of the electromechanical system of
ii is a rear perspective cross-sectional view of the electromechanical system and fluid transfer device shown
Various systems, methods, and components can be used in different embodiments of the inventions. Some embodiments are illustrated in the accompanying figures; however, the figures are provided for convenience of illustration only, and should not be interpreted to limit the inventions to the particular combinations of features shown. Rather, any feature, structure, material, step, or component of any embodiment described and/or illustrated in this specification can be used by itself, or with or instead of any other feature, structure, material, step, or component of any other embodiment described and/or illustrated in this specification. Nothing in this specification is essential or indispensable.
The fluid transfer module 31 can comprise a multidirectional flow-control valve 41 and an intermediate container or pumping region 40, as well as any connector(s) and/or conduit(s) that may extend between or among these or any other components of the fluid transfer module 31, and/or any connectors and/or conduits that may extend between or among the fluid transfer module 31 and the source container 39 and/or the destination container 44. For example, the fluid transfer module 31 can comprise an inlet fluid connector 32 and tubing that can be configured to removably attach the multidirectional flow-control valve to the source container 39; and/or the fluid transfer module 31 can comprise an outlet fluid connector 42 and tubing that can be configured to removably attach the multidirectional flow control valve to the destination container 44.
As shown in
The multidirectional flow-control valve 41 can be configured to mechanically attach to or interface with the electromechanical controller 36. For example, in some embodiments, the multidirectional flow-control valve 41 can comprise a driving interface 33 that is configured to attach with and/or interface with a corresponding electromechanical driver (see, e.g.,
In some embodiments, the multidirectional flow-control valve 41 can comprise a stopcock with a plurality of functional positions, such as a first position that enables fluid communication between the outlet fluid connector 42 and the intermediate container or pumping region 40 (but not the inlet fluid connector 32, in some embodiments); a second position that enables fluid communication between the inlet fluid connector 32 and the intermediate container or pumping region 40 (but not the outlet fluid connector 42, in some embodiments); and a third position that enables fluid communication between the outlet fluid connector 42 and the inlet fluid connector 32 (but not the intermediate container or pumping region 40, in some embodiments). For example, in some embodiments, when the stopcock is in the first position, fluid can flow from the intermediate container or pumping region 40 to the destination container 44 or vice versa; when the stopcock is in the second position, fluid can flow from the source container 39 to the intermediate container or pumping region 40 or vice versa; and when the stopcock is in the third position, fluid can flow from the source container 39 to the destination container 44 or vice versa. Further, in some embodiments, when the stopcock is in the first position, the intermediate fluid connector 38, the stopcock, and the outlet fluid connector 42 can comprise at least a portion of a flow path between the intermediate container or pumping region 40 and the destination container 44; when the stopcock is in the second or fourth position, the inlet fluid connector 32, the stopcock, and the intermediate fluid connector 38 can comprise at least a portion of a flow path between the source container 39 and the intermediate container or pumping region and when the stopcock is in the third position, the inlet fluid connector 32, the stopcock, and the outlet fluid connector 42 can comprise at least a portion of a flow path between the source container 39 and the destination container 44. In some embodiments, the stopcock can comprise at least a portion of one or more flow paths between or among two or more containers (e.g., the source container 39, the intermediate container or pumping region 40, and/or the destination container 44) without the use of any connectors (e.g., the inlet fluid connector 32, the intermediate fluid connector 38, and/or the outlet fluid connector 42) when in the first, second, third, and/or fourth position. Other arrangements can be used are also appreciated and contemplated herein, including, for example, stopcocks configured to have more or less than three positions (e.g., stopcocks configured to have 2, 4, 5, or more positions).
In some embodiments, the fluid transfer module 31 can be a single-use or limited-use, disposable device that is configured to be periodically removed from and replaced within the fluid transfer device 30, such as after a single dosage of medication for a particular patient has been transferred and/or after one particular type of medication has passed through the fluid transfer module 31 (e.g., to avoid mixing of medications when not desired).
The various components of the fluid transfer system 86 can communicate between or among themselves in any suitable manner, as identified in
The user interface 78 can communicate with one or more fluid transfer devices 30 and/or with one or more patient and/or drug information storage device(s) or network(s) 70 by way of any suitable electronic communication device 76, including by way of any wireless device or by way of any other of the electronic communicators. In some embodiments of the fluid transfer management system 74 in which there are multiple fluid transfer devices 30, a single user interface 78 can electronically communicate with a plurality of fluid transfer devices 30 to control and/or monitor multiple fluid transfers operating generally simultaneously or generally in parallel. In some embodiments of the fluid transfer management system 74 in which there are multiple fluid transfer devices 30, one or more user interfaces 78 can electronically communicate with a plurality of fluid transfer devices 30 to control and/or monitor multiple fluid transfers operating generally simultaneously or generally in parallel. The user interface 78, like the fluid transfer device 30, can electronically communicate with or include a memory 84 by way of a wired connector 80 or any other of the electronic communicators. The memory 84 of the user interface 78 can be part of the user interface 78 in that a common housing can be provided for containing or supporting both. Each of the components of the fluid transfer management system 74 as shown in
i-2Di illustrate various features, components, and arrangements that can be included in some embodiments of the fluid transfer device 30 and fluid transfer module 31 shown in
Turning to
In some embodiments, at least one or more portions of the housing 202, such as the one or more receptacles 218 (e.g., the recess 218 illustrated in
The volume sensor can be used, for example, to control and/or to provide a record of the volume and/or type of fluid transferred to a patient, such as, for example, by sensing and/or recording the volume and/or one or more other characteristics (e.g., color, viscosity, concentration, lot number, expiration date, etc.) of the liquid in a container (e.g., the intermediate container, or pumping region 40, and/or the source container 39 and/or the destination container 44) before, during, and/or after it is transferred to a patient. For example, in some embodiments, a camera can be used to capture an image of the intermediate container or pumping region 40 to confirm or measure the volume therein. A data file can then be created and stored in a memory 84 which has one of more items of information, such as patient identifying information, the date and time the liquid was transferred and/or the volume or other characteristic(s) of the liquid was or were confirmed and recorded, the type (name, brand, and/or concentration, etc.) of medical fluid transferred, the volume of medical fluid transferred, and/or one or more images of the intermediate container or pumping region 40 with liquid inside, etc. The same or a similar data file can be created for any one of the suitable volume sensors described above. In some embodiments, the fluid transfer unit 200, the fluid transfer device 30, and/or the fluid transfer system 86 can include one or more measuring instruments, such as one or more volume sensors. In some embodiments, the one or more measuring instruments or volume sensors can be internal and/or external to the fluid transfer unit 220, or partially external and partially internal, such as when a portion of the instrument or sensor is inside of the housing 212 and a portion of the sensor protrudes from the housing 212.
i illustrates a rear view of an example of a fluid transfer module 31 of
A multidirectional flow-control valve 41, such as a fluid stopcock 230, can be particularly useful in some embodiments because it can permit variability and control of the direction and/or orientation of the fluid pathway within the fluid transfer module 31. In some embodiments, the flow-control valve 41 can be configured, as illustrated throughout this specification, to selectively enable a plurality of discrete settings, each setting enabling fluid connections within the fluid pathway of the fluid transfer module 31 among two or more different components of the fluid transfer module 31, and closing-off or isolating one or more other fluid connections of one or more other components from the fluid pathway of the fluid transfer module 31. The flow-control valve 41 can be configured to change between the plurality of discrete settings.
In some embodiments, as illustrated, such change or changes of settings or connections within the flow-control valve 41 can be accomplished electronically and independently of changes to fluid pressure within the fluid transfer module 31. For example, in some embodiments, a pressure differential can arise between two or more parts or components of the fluid transfer module 31 without causing any change of connections within the fluid transfer module 31 and/or without enabling fluid communication between different portions of the fluid transfer module 31 that, before such pressure differential, were not previously in fluid communication with each other.
In some embodiments, the multidirectional flow-control valve 41 is not a one-way valve or a series of one-way valves; rather, the multidirectional flow-control valve 41, in each particular electronically selectable setting, can provide a full two-way fluid pathway between two or more components of the fluid transfer module 31. For example, in some embodiments, in one or a plurality of discrete, electronically selectable settings, the flow-control valve 41 can provide a two-way fluid pathway between the inlet fluid connector 226 and the outlet fluid connector 234; and/or a two-way fluid pathway between the inlet fluid connector 226 and the intermediate container 40 or syringe pump 240; and/or a two-way fluid pathway between the intermediate container 40 or syringe pump 240 and the outlet fluid connector 234. In some embodiments, the multidirectional flow-control valve 41 can enable fluid withdrawn from a source container 39 to be partially or fully returned to a source container 39, in some situations, which can be particularly advantageous, such as, for example, during priming and/or purging of a fluid transfer module 31, although other situations in which this type of fluid flow are also contemplated and can be used.
In some embodiments, either or both of the fluid connectors 226, 234 can be industry standard medical connectors (e.g., luer connectors complaint with ISO 594 or compliant with any other industry standard) that are resealable and fluid-tight, such as the Clave® female medical connector or the Spiros® male medical connector or either of the male or female sides of a Chemolock® medical connector system, all sold by ICU Medical, Inc. Examples of embodiments of these and other devices, among many others, that can be used as fluid connectors 226, 234, or as any portions thereof, are included in U.S. Pat. Nos. 5,873,862; 7,998,134; and U.S. Published Patent Application No. 2014/0246616, all of which are incorporate by reference in this specification in their entireties. Any feature, structure, material, step, or component described and/or illustrated in any of the foregoing patents or published application can be used with or instead of any feature, structure, material, step, or component described and/or illustrated in any other portion of this specification.
In some embodiments, the fluid stopcock 230 can comprise a device that selectively permits fluid communication between and/or among multiple apertures and/or channels in the stopcock 230. For example, as shown in
i is a magnified partial front view of the fluid transfer unit 200 of
Returning to
In some embodiments, as shown, for example, in
As illustrated, in some embodiments, the fluid transfer module 31 (such as the fluid pump assembly 224) can form part of or constitute a closed system, in that: (i) liquid, or fluid, and/or vapors contained or sealed within the fluid transfer module 31 are prevented from exiting or escaping from the fluid transfer module 31, and/or (ii) the exiting or escaping of liquid, or fluid, and/or vapors is resisted in a clinically significant manner to diminish or avoid one or more clinical risks or negative outcomes, when the fluid transfer module 31 is disconnected from other components of the fluid transfer device 30. As shown, in some embodiments, the entire fluid pathway within the fluid transfer device 30 can constitute a closed system or a seal system. As used in this specification, the term “closed system” or “sealed” or any similar terms are used in accordance with their customary meanings in the field of medical infusion, and these terms include the requirement that fluids stay inside of the fluid transfer module 31 or the fluid transfer device 30 (or components thereof) under normal conditions or use such that any small amount of escaping fluid or vapors would not have any significant adverse clinical effects under normal conditions or use. In some embodiments, as shown in
i is a front perspective view of another type of fluid transfer module 31 that is removably attached to the fluid transfer unit 200 of
When the fluid transfer module 31 (e.g., the fluid pump assembly 224) is removably attached to the fluid transfer unit 200, a fluid-observation region on the conduit 238 of the fluid transfer device 30 can be positioned adjacent to or within an appropriate sensing distance from the one or more sensors 215. In the illustrated example, the fluid-observation region of the fluid transfer device 30 is at least a portion of the conduit 238 positioned between the multidirectional flow-control valve 41 (e.g., the fluid stopcock 230) and/or the intermediate container or pumping region 40 (e.g., the syringe pump 240). In some embodiments, the fluid-observation region of the fluid transfer device 30 can comprise a portion of the conduit 238 positioned between the multidirectional flow-control valve 41 (e.g., the fluid stopcock 230) and/or the intermediate container or pumping region 40 (e.g., the syringe pump 240). In some embodiments, the fluid-observation region can be positioned in another position on the fluid transfer device 30, or there can be multiple fluid-observation regions 30 located at a plurality of positions on the fluid transfer device 30.
In some embodiments, the one or more sensors 215 can be configured to determine whether there is liquid, gas (e.g., one or more bubbles), and/or a vacuum or partial vacuum, within a particular region or regions of the fluid transfer module 31 (e.g., fluid pump assembly 224). For example, as illustrated in the figures, the one or more sensors 215 can be configured to determine whether there is a medical fluid within at least a portion of the conduit 238 or whether there is a gas (e.g., ambient air or air bubbles) or a vacuum or partial vacuum within the conduit 238. In some embodiments, the one or more sensors 215 can determine whether there is a medical fluid within a portion of the conduit 238 or whether there is a gas (e.g., ambient air) or a vacuum or partial vacuum within a portion of the conduit 238. The one or more sensors 215 can be any suitable type of sensor, including but not limited to one or more acoustic sensors (e.g., ultrasonic sensors), infrared sensors, laser sensors, visual-spectrum optical sensors, motion flow sensors, or any other suitable sensors. One or more indicators 216, such as an indicator light or indicator speaker or other indicator, can be positioned on the sensor device 214 to indicate when the sensor device 214 is sensing a particular condition, such as when liquid is present in the fluid observation-region.
i also illustrates a fluid source container 39 in the form in this example of an inverted vial 246 attached to a vial adaptor 248 that is in turn attached to an inlet connector 32 in the form in this example of a male fluid connector 226a with a longitudinal locking mechanism. In some embodiments, the vial adaptor 248 comprises a filtered fluid inlet and/or outlet 250 and securing arms that are configured to securely receive the vial.
ii-2Dii illustrate various features, components, and arrangements that can be included in some embodiments of the fluid transfer device 30 shown in
As another example,
In some embodiments, the stopcock handle 245 can be removably attached to the stopcock 230. In some embodiments, the handle is configured to be manipulated (e.g., rotated, slid, pushed, and/or pulled) to manually actuate the stopcock into the various positions described above with reference to, for example,
ii is a rear perspective cross-sectional view of the fluid transfer unit 200 and the fluid pump assembly 224 shown in
The fluid transfer unit 200 may comprise one or more computer processors 297, 298, which can form part of or be in electronic communication with any or all of the electro-mechanical controller 36 of
In some embodiments, the fluid transfer unit 200 may comprise one or more presence sensors 294a, 294b, 294c. The one or more sensors 294a, 294b, 294c can be positioned within and/or on the housing 202 and can determine the presence or absence of one or more structures. In some embodiments, one or more of the sensors 294a, 294b, 294c can be infrared sensors or any other suitable sensor. One or more of the sensors 294a, 294b can determine whether the fluid source container 39 (such as vial 246), the source adapter 250, and/or the source fluid connector are present and/or connected to the fluid transfer unit 200. In some embodiments, sensor 294a may determine if a source container 246 connector, such as a male or female side of a Chemolock® medical connector system, is properly engaged with a corresponding connector on the fluid transfer unit 200, such as a Chemolock® connector 226a. The sensor 294b may determine if an intermediate container such as fluid pump assembly 224, and/or connector 226a, such as a male or female side of a Chemolock® connector, is present and/or properly engaged with the housing 202 and/or a corresponding connector on a source container 246. The sensor 294c may determine whether the destination container 44, such as IV bag 244, and/or destination fluid connector are present and/or connected to the fluid transfer unit 200. In some embodiments, sensor 294c may determine if a destination container 44 connector, such as a male or female side of a Chemolock® medical connector system, is properly engaged with a corresponding connector on the fluid transfer unit 200, such as a Chemolock® connector 234a. In some embodiments, if any of sensor 294a, 294b, 294c determine that a component of the fluid transfer unit 200 is not present, the sensor 294a, 294b, 294c may send a signal to the controller 36 to prevent initiation of the fluid transfer process and/or terminate an ongoing fluid transfer. The sensor 294a, 294b, 294c may trigger an indicator signaling to a user that not all components are present or properly engaged with the fluid transfer unit 200.
As shown in
In some embodiments, one or more of the sensors 294a, 294b, 294c can be configured to detect the presence or absence of at least a portion of a fluid transfer module attached to the electronic fluid transfer device, such as a connector on the fluid transfer device. In some embodiments, one or more of the sensors (e.g., 294a, 294b) can be configured to additionally or alternatively detect the presence or absence of or connection with at least a portion of a fluid source system, such as a connector or vial adaptor or vial or bag or conduit that forms part of or is connected to a fluid source system. In some embodiments, one or more of the sensors (e.g., 294c) can be configured to additionally or alternatively detect the presence or absence of or connection with at least a portion of a fluid destination system, such as a connector or bag or conduit that forms part of or is connected to a fluid destination system. In some embodiments, the detection of one or more of the fluid transfer module 31, the detection of the connection to the fluid source system, and/or the detection to the connection to the fluid destination system can be a gating step or a required step for the computer processor or other component of the electro-mechanical controller to permit fluid transfer to begin or continue.
The user interface 78 can display or convey various items of information between a user and an electronic storage medium and/or can convey one or more executable instructions to a computer processor in the fluid transfer unit 200, or to electromechanical hardware in the fluid transfer unit 200, to perform one or more actions relating to fluid transfer. For example, the user interface 78 can receive and/or store (e.g., by user input or electronic transmission) the identity of the pharmacist or technician who is performing the fluid transfer, the identity of the patient, the name of the medical fluid, the volume of medical fluid to be transferred, the lot number, the expiration date of the medical fluid, and/or the date and time on which the fluid transfer was performed, etc. Also, as other examples, the user interface 78 can assist in controlling the fluid transfer by receiving and conveying commands from the user via the user interface 78 and/or displaying messages from the fluid transfer unit 200 regarding the progress and/or status of the fluid transfer, such as commands initiating the fluid transfer and/or halting the fluid transfer, and/or one or more messages demonstrating the amount of fluid transferred at any given moment, or the history of fluid transfers for a particular patient or pharmacist over a particular period, or one or more error messages indicating that the fluid transfer was not completed or that the fluid source container 39 is not connected or is empty, or the fluid destination container 44 is not connected or is full, or any other useful message.
As shown in
As shown in
In some embodiments, the bubble trap 15 can be provided as an adapter to be coupled to a container (e.g., the destination and source containers 44, 39). For example, in some embodiments, the bubble trap 15 can be provided in a package with a container. For example, in some embodiments, the bubble trap 15 can be provided in a package with a syringe, with a cassette, with a fluid bag, with a fluid line, etc. It will be appreciated that the package can include more or less components, assembled or disassembled.
With further reference to
In some embodiments, once the destination container 44 is filled with fluid, the fluid transfer module 45 can be disconnected from the fluid source 39 and then connected to a patient. For example,
As shown in
As shown in
In some embodiments, the one or more projections can be configured to maximize the air trapping ability and/or capability of the chamber 17. For example, in some embodiments, one or more projections (e.g., projection 18) can be positioned so that the opening 16c of the outlet projection channel 19 is near or in the center of the chamber 17. This can advantageously minimize the chance of air (e.g., one or more air bubbles) entering the outlet 16b after it comes to rest somewhere along the periphery of the chamber 17. In some embodiments, as shown in the drawings, the opening 16c of the outlet projection channel 19 may have an outlet center axis that is misaligned and/or offset from an inlet center axis of the inlet 16a. For example, as shown in the drawings, the opening 16c may have a center axis that is generally perpendicular to a plane defined by the opening 16c. In some embodiments, the center axis of the opening 16c may be offset from at least one of a center axis of the inlet 16a and a center axis of the outlet 16b. The opening 16c being misaligned from one or more of the inlet 16a and the outlet 16b breaks up a fluid pathway from the inlet 16a to the outlet 16b, thereby causing any air bubbles to rest along a periphery of the chamber 17. This may facilitate the collection of air within the bubble trap 15. As shown in
In some embodiments, as shown in the drawings the opening 16c of the outlet projection channel 19 may be smaller relative to the inlet 16a of the bubble trap 15. The smaller size of the opening 16c can advantageously minimize that amount of air that is transferred through the outlet projection channel 19. The size of the opening 16c may increase the force required to push fluid into and/or through the outlet projection channel 19. The bubble trap 15 may be used with an automated compounder, as described herein, to drive fluid through the opening 16c of the bubble trap 15. However, it will be understood that the opening 16c of the bubble trap 15 may comprise any suitable size and/or shape to permit the transfer of fluid into and/or through the outlet projection channel 19. For example, the opening 16c of the outlet projection channel 19 may be configured to permit the transfer of fluid with the use of a manual compounder (e.g. a syringe). It will also be appreciated that the tips of the one or more projections (e.g., projection 18) can be configured to deflect bubbles that collide or otherwise come in close proximity to the outlet projection 18. It will be further appreciated that the shape of the one or more projections can have any suitable shape, such as, for example, straight, curved, cylindrical, tapered, conical (e.g., projection 18), etc. The flow of fluid and gas through the chamber 17 will be described in more detail below with reference to
The bubble trap 15 can have any suitable fluid capacity, or internal volume, including from about 1 cc to about 2 cc, from about 1 cc to about 5 cc, from about 1 cc to about 10 cc, greater than about 1 cc, greater than about 2 cc, and/or less than about 20 cc, among others (e.g., from about 3 cc to about 4 cc, from about 5 cc to about 10 cc, etc.). Any suitable portion of this fluid capacity can be used to trap air, such as, for example, 10% or less of the capacity, 20% or less of the capacity, 30% or less of the capacity, 40% or less of the capacity, 50% or less of the capacity, 60% or less of the capacity, or 70% or less of the capacity. Other percentages, more or less, as well as ranges, narrower or wider, are also appreciated. In some embodiments, the trapping capacity of the bubble trap 15 can be constant irrespective of the position of the bubble trap 15. In other embodiments, the trapping capacity of the bubble trap 15 can depend on myriad factors, such as the size and shape of the chamber 17, the length of the one or more projections and the locations of their openings, and/or the orientation of the bubble trap 15 with respect to fluid flow and gravity. For example, when in the orientation shown in
As a result of some or all of the foregoing features, the bubble trap 15 can trap bubbles released from a source container (e.g., source container 39), a destination container (e.g., destination container 44), and/or a component connected to a fluid line. As shown in
In some embodiments, the bubble trap 15 can be attached to a fluid line for use with any suitable pump and/or fluid transfer device (e.g., fluid transfer device 30, fluid transfer unit 200, and/or fluid pump assembly 224, etc.). For example, in some embodiments, the bubble trap 15 can be configured to be used with and/or fluidically connected to an ambulatory infusion pump, including infusion pumps that are configured to provide computerized ambulatory drug delivery. While the bubble trap 15 is discussed herein for use with a fluid transfer pump, it will be understood by one of skill in the art that a fluid transfer need not be used with the bubble trap 15. For example, the bubble trap 15 may be used to manually fill a destination container by hand.
In some embodiments, the bubble trap 15 can configured to be used with and/or fluidically connected to CADD® pumps manufactured by SMITHS MEDICAL®.
As shown in
As described above, the position of the bubble trap 15 between the cassette 24a and the air detection sensor 26 can advantageously reduce the number of air detection alarms (e.g., indications) by trapping air before it is allowed to pass through the outlet 16b of the bubble trap 15 and into the male-to-male conduit 28. As a result, the use of the bubble trap 15 can advantageously translate into fewer treatment interruptions, and therefore enable the pump 22 to provide patients with more consistent and continuous treatment. This, in combination with the ability of the bubble trap 15 to reduce the risk of air embolisms, can increase patient confidence in the pump 22. By trapping air, the bubble trap 15 can enhance patient comfort by reducing and/or eliminating minor air embolisms that, while not lethal, can be nevertheless painful or uncomfortable. The bubble trap 15 can also prevent major air embolisms that are potentially lethal or would otherwise require medical intervention if not prevented from being infused into the patient. As will be described in more detail below with reference to
The fluid transfer protocol 900 begins at the start block 902. The protocol 900 continues in block 904 with removing a cassette 24 from a package. In some embodiments, the cassette 24 can include a reservoir 25. In block 906, the protocol continues with attaching a bubble trap 15 (e.g., an omnidirectional bubble trap) to the cassette 24, the source container 39, and/or destination container 44. At block 908, the bubble trap 15 and the cassette 24 are fluidically connected to an automated or manual compounder (or a compounder capable of both), such as, for example, to a fluid transfer device (e.g., fluid transfer device 30 or a syringe configured to manually deliver fluid to the cassette 24). In 910, the protocol continues with applying a vacuum to the bubble trap 15 and the cassette 24 with the compounder to remove air inside of each and push it into a source container (e.g., source container 39 and/or destination container 44). In some embodiments, the compounder (or any suitable fluid transfer device) is capable of generating a vacuum in the bubble trap 15 and/or the cassette 24 (e.g., in the reservoir 25 of the cassette 24). For example, in some embodiments, the vacuum can be above or below atmospheric pressure. As described above, the vacuum applied can be sufficient to reduce the volume of the bubble trap 15, such as, for example, by collapsing the chamber 17 of the bubble trap 15. The flexible (e.g., collapsible) rigid and/or semi-rigid material of the bubble trap 15 can advantageously allow gas to be removed from the bubble trap 15 at lower vacuum pressure relative to the vacuum that would otherwise be required to remove an equivalent amount of gas from the bubble trap 15 if the material did not comprise flexible rigid and/or semi-rigid material. At block 912, the protocol continues with pushing medical fluid into the reservoir 25 of the cassette 24 with the compounder. In some embodiments, one or more fluids can be pushed into the reservoir 25 by the compounder. Blocks 914 and 916 of the protocol continue with detaching the bubble trap 15 and the cassette 24 from the fluid transfer device and then attaching the bubble trap 15 and the cassette 24 to the pump 22, respectively. At block 918, the process ends with pumping fluid in the reservoir 25 of the cassette 24 past the bubble trap 15 and into a patient. However, it will be understood, that in some embodiments, the process can end with pumping fluid in past the bubble trap 15 and into a source container 39 and/or destination container 44. From there, in some embodiments the fluid can be pumped from the source container 39 to the patient without the use of a bubble trap 15. Similarly, in some embodiments, the fluid can be pumped from the destination container 44 to the patient without the use of a bubble trap 15.
With continued reference to infusion pumps such as the pump 22 illustrated in
As shown in
In some embodiments, the outlet region 103 may be located on a bottom portion of the reservoir 25. As air bubbles rise to the top of the reservoir 25, the location of the outlet region 103 on the bottom portion can reduce the amount of air bubbles that are passed through the outlet region 103 and one or more connectors 105, 106. As a result, the location of the outlet region 103 may advantageously reduce the number of air detection alarms and translate into fewer treatment interruptions, and therefore enable the pump 22 to provide patients with more consistent and continuous treatment. This, in combination with the ability of the bubble trap 15 to reduce the risk of air embolisms, can increase patient confidence in the pump 22.
As illustrated in
Any system, method, and device described in this application can include any combination of the preceding features described in this and other paragraphs, among other features and combinations described herein, including features and combinations described in subsequent paragraphs.
Although this invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while several variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. It should be understood that various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow. Moreover, language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “approximately”, “about”, and “substantially” as used herein include the recited numbers (e.g., about 10%=10%), and also represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
This application is a continuation of U.S. patent application Ser. No. 17/240,021, filed on Apr. 26, 2021, and issued as U.S. Pat. No. 11,583,637 on Feb. 21, 2023, which is a continuation of U.S. patent application Ser. No. 16/255,710, filed on Jan. 23, 2019, and issued as U.S. Pat. No. 11,020,541 on Jun. 1, 2021, which claims the benefit under 35 U.S.C. § 120 and 35 U.S.C. § 365(c) as a continuation of International Application No. PCT/US2017/043761, designating the United States, with an international filing date of Jul. 25, 2017, entitled “SYSTEMS, METHODS, AND COMPONENTS FOR TRAPPING AIR BUBBLES IN MEDICAL FLUID TRANSFER MODULES AND SYSTEMS,” which claims priority to U.S. Application No. 62/366,509, filed Jul. 25, 2016, titled “SYSTEMS, METHODS, AND COMPONENTS FOR TRAPPING AIR BUBBLES IN MEDICAL FLUID TRANSFER MODULES AND SYSTEMS,” the entire contents of each of which are incorporated by reference herein and made a part of this specification.
Number | Name | Date | Kind |
---|---|---|---|
1923501 | Perry | Aug 1933 | A |
2597699 | Bauer | May 1952 | A |
3157201 | Littmann | Nov 1964 | A |
3204633 | Hofstra | Sep 1965 | A |
3295297 | Collins | Jan 1967 | A |
3344785 | Hamilton | Oct 1967 | A |
D222956 | Sato | Feb 1972 | S |
D222957 | Sato | Feb 1972 | S |
3778973 | Martinez | Dec 1973 | A |
3803810 | Rosenberg | Apr 1974 | A |
3834124 | Ichikawa | Sep 1974 | A |
D236163 | Manno | Jul 1975 | S |
3935883 | Stach et al. | Feb 1976 | A |
4005710 | Zeddies et al. | Feb 1977 | A |
4084606 | Mittleman | Apr 1978 | A |
4085047 | Thompson | Apr 1978 | A |
4102655 | Jeffery et al. | Jul 1978 | A |
4187890 | Stach et al. | Feb 1980 | A |
4190048 | Sampson | Feb 1980 | A |
4262671 | Kersten | Apr 1981 | A |
4306705 | Svensson | Dec 1981 | A |
4336802 | Stone et al. | Jun 1982 | A |
4341538 | Vadnay et al. | Jul 1982 | A |
4367736 | Gupton | Jan 1983 | A |
D268206 | Kosako | Mar 1983 | S |
D268284 | Manno et al. | Mar 1983 | S |
4397335 | Doblar et al. | Aug 1983 | A |
4410321 | Pearson et al. | Oct 1983 | A |
4423741 | Levy | Jan 1984 | A |
4519792 | Dawe | May 1985 | A |
4534758 | Akers et al. | Aug 1985 | A |
4559043 | Whitehouse et al. | Dec 1985 | A |
4561856 | Cochran | Dec 1985 | A |
4568330 | Kujawski et al. | Feb 1986 | A |
4643713 | Vitala | Feb 1987 | A |
4666429 | Stone | May 1987 | A |
4670007 | Wheeldon et al. | Jun 1987 | A |
4683916 | Raines | Aug 1987 | A |
4755172 | Baldwin | Jul 1988 | A |
4759756 | Forman et al. | Jul 1988 | A |
4768568 | Fournier et al. | Sep 1988 | A |
4778450 | Kamen | Oct 1988 | A |
4819684 | Zaugg et al. | Apr 1989 | A |
4828587 | Baurmeister et al. | May 1989 | A |
4863429 | Baldwin | Sep 1989 | A |
D305165 | Rudolph et al. | Dec 1989 | S |
4922975 | Polaschegg | May 1990 | A |
4936841 | Aoki et al. | Jun 1990 | A |
4969874 | Michel et al. | Nov 1990 | A |
4972876 | Kabata et al. | Nov 1990 | A |
4976590 | Baldwin | Dec 1990 | A |
4995268 | Ash et al. | Feb 1991 | A |
5024347 | Baldwin | Jun 1991 | A |
5037390 | Raines et al. | Aug 1991 | A |
5114580 | Ahmad et al. | May 1992 | A |
D328952 | Arioka | Aug 1992 | S |
5176658 | Ranford | Jan 1993 | A |
5211201 | Kamen et al. | May 1993 | A |
5224937 | van der Heiden et al. | Jul 1993 | A |
5254096 | Rondelet et al. | Oct 1993 | A |
5256155 | Yerlikaya et al. | Oct 1993 | A |
5288290 | Brody | Feb 1994 | A |
5300044 | Classey et al. | Apr 1994 | A |
D348101 | Poli et al. | Jun 1994 | S |
5334211 | Shiber | Aug 1994 | A |
5336201 | von der Decken | Aug 1994 | A |
D352778 | Irvin | Nov 1994 | S |
5378231 | Johnson et al. | Jan 1995 | A |
5405333 | Richmond | Apr 1995 | A |
5415583 | Brandt, Jr. | May 1995 | A |
5423791 | Bartlett | Jun 1995 | A |
5431201 | Torchia et al. | Jun 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5466220 | Brenneman | Nov 1995 | A |
5609572 | Lang | Mar 1997 | A |
5645538 | Richmond | Jul 1997 | A |
5647845 | Haber et al. | Jul 1997 | A |
5674199 | Brugger | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5776345 | Truitt et al. | Jul 1998 | A |
5782816 | Werschmidt et al. | Jul 1998 | A |
5807312 | Dzwonkiewicz | Sep 1998 | A |
5810792 | Fangrow, Jr. et al. | Sep 1998 | A |
5824212 | Brockhoff | Oct 1998 | A |
5830165 | Block, Jr. | Nov 1998 | A |
5871110 | Grimard et al. | Feb 1999 | A |
5871500 | Jepson et al. | Feb 1999 | A |
5885270 | Ortiz et al. | Mar 1999 | A |
D408079 | Ellis | Apr 1999 | S |
5897526 | Vaillancourt | Apr 1999 | A |
5904666 | DeDecker et al. | May 1999 | A |
5910252 | Truitt et al. | Jun 1999 | A |
5935106 | Olsen | Aug 1999 | A |
5947951 | Ortiz et al. | Sep 1999 | A |
5968014 | Neftel et al. | Oct 1999 | A |
5989237 | Fowles et al. | Nov 1999 | A |
6059747 | Bruggeman et al. | May 2000 | A |
6110153 | Davis et al. | Aug 2000 | A |
RE36871 | Epstein et al. | Sep 2000 | E |
6123685 | Reynolds | Sep 2000 | A |
6132404 | Lopez | Oct 2000 | A |
6152900 | Mayer | Nov 2000 | A |
6171484 | Schnell et al. | Jan 2001 | B1 |
6179823 | Niedospial, Jr. | Jan 2001 | B1 |
6193675 | Kraus et al. | Feb 2001 | B1 |
6193689 | Woodard | Feb 2001 | B1 |
6202708 | Bynum | Mar 2001 | B1 |
6221041 | Russo | Apr 2001 | B1 |
6245048 | Fangrow, Jr. et al. | Jun 2001 | B1 |
6287289 | Niedospial, Jr. | Sep 2001 | B1 |
6302864 | Nowosielski | Oct 2001 | B1 |
6425497 | Chu et al. | Jul 2002 | B1 |
6474375 | Spero et al. | Nov 2002 | B2 |
6485472 | Richmond | Nov 2002 | B1 |
6537356 | Soriano | Mar 2003 | B1 |
6551299 | Miyoshi et al. | Apr 2003 | B2 |
6558365 | Zinger et al. | May 2003 | B2 |
6572256 | Seaton et al. | Jun 2003 | B2 |
6585229 | Cote, Sr. et al. | Jul 2003 | B2 |
6590167 | Clare | Jul 2003 | B2 |
6599273 | Lopez | Jul 2003 | B1 |
6623455 | Small et al. | Sep 2003 | B2 |
6629956 | Polidoro et al. | Oct 2003 | B1 |
6651956 | Miller | Nov 2003 | B2 |
6663586 | Verkaart et al. | Dec 2003 | B2 |
6689108 | Lavi et al. | Feb 2004 | B2 |
6699230 | Jaafar et al. | Mar 2004 | B2 |
6711460 | Reese | Mar 2004 | B1 |
6726672 | Hanly et al. | Apr 2004 | B1 |
6793651 | Bennett et al. | Sep 2004 | B1 |
6813868 | Baldwin et al. | Nov 2004 | B2 |
6854620 | Ramet | Feb 2005 | B2 |
6877530 | Osborne et al. | Apr 2005 | B2 |
6908459 | Harding et al. | Jun 2005 | B2 |
6915823 | Osborne et al. | Jul 2005 | B2 |
6948522 | Newbrough et al. | Sep 2005 | B2 |
6953450 | Baldwin et al. | Oct 2005 | B2 |
6985870 | Martucci et al. | Jan 2006 | B2 |
6991002 | Osborne et al. | Jan 2006 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
6997917 | Niedospial, Jr. et al. | Feb 2006 | B2 |
7006894 | De La Huerga | Feb 2006 | B2 |
7017623 | Tribble et al. | Mar 2006 | B2 |
7086431 | D'Antonio et al. | Aug 2006 | B2 |
7108024 | Navarro | Sep 2006 | B2 |
7117901 | Martinell Gisper-Sauch et al. | Oct 2006 | B2 |
7117902 | Osborne | Oct 2006 | B2 |
7128105 | Tribble et al. | Oct 2006 | B2 |
7163031 | Graves et al. | Jan 2007 | B2 |
7163035 | Khan et al. | Jan 2007 | B2 |
7175615 | Hanly et al. | Feb 2007 | B2 |
7194336 | DiGianfilippo et al. | Mar 2007 | B2 |
7260447 | Osborne | Aug 2007 | B2 |
7317967 | DiGianfilippo et al. | Jan 2008 | B2 |
7343224 | DiGianfilippo et al. | Mar 2008 | B2 |
7343943 | Khan et al. | Mar 2008 | B2 |
7351226 | Herskowitz | Apr 2008 | B1 |
7354426 | Young | Apr 2008 | B2 |
7392638 | Baldwin et al. | Jul 2008 | B2 |
7396051 | Baldwin et al. | Jul 2008 | B2 |
7398802 | Baker | Jul 2008 | B2 |
7416981 | Baker et al. | Aug 2008 | B2 |
7442186 | Blomquist | Oct 2008 | B2 |
7488311 | Domkowski et al. | Feb 2009 | B2 |
7499581 | Tribble et al. | Mar 2009 | B2 |
7527619 | Domkowski et al. | May 2009 | B2 |
7530211 | McErlean et al. | May 2009 | B2 |
7530974 | Domkowski et al. | May 2009 | B2 |
7538858 | Mackey | May 2009 | B2 |
D594120 | Berberich et al. | Jun 2009 | S |
D596291 | Berberich et al. | Jul 2009 | S |
7566326 | Duchon et al. | Jul 2009 | B2 |
7610115 | Rob et al. | Oct 2009 | B2 |
7630788 | Reese | Dec 2009 | B1 |
7630789 | Broadfield et al. | Dec 2009 | B2 |
7632261 | Zinger et al. | Dec 2009 | B2 |
7654976 | Peterson et al. | Feb 2010 | B2 |
7681606 | Khan et al. | Mar 2010 | B2 |
7685026 | McGrady et al. | Mar 2010 | B1 |
D616092 | Domkowski et al. | May 2010 | S |
7717697 | Burg et al. | May 2010 | B2 |
D620108 | Eitenmueller et al. | Jul 2010 | S |
7753085 | Tribble et al. | Jul 2010 | B2 |
7758660 | Connell et al. | Jul 2010 | B2 |
7789850 | Roger | Sep 2010 | B2 |
7814731 | Bender et al. | Oct 2010 | B2 |
7850051 | Py et al. | Dec 2010 | B2 |
7867215 | Akerlund et al. | Jan 2011 | B2 |
7882863 | Pestotnik et al. | Feb 2011 | B2 |
7900658 | Osborne et al. | Mar 2011 | B2 |
7913720 | Tribble et al. | Mar 2011 | B2 |
7963201 | Willoughby et al. | Jun 2011 | B2 |
7963954 | Kavazov | Jun 2011 | B2 |
7967202 | Durrell et al. | Jun 2011 | B2 |
7981381 | Lurvey et al. | Jul 2011 | B2 |
8034041 | Domkowski et al. | Oct 2011 | B2 |
8037659 | Osborne et al. | Oct 2011 | B2 |
8075545 | Moy et al. | Dec 2011 | B2 |
8091727 | Domkowski | Jan 2012 | B2 |
8091860 | Thompson et al. | Jan 2012 | B2 |
8104644 | Py et al. | Jan 2012 | B2 |
8117809 | McErlean et al. | Feb 2012 | B2 |
8140351 | Tribble et al. | Mar 2012 | B2 |
8141601 | Fehr et al. | Mar 2012 | B2 |
8151835 | Khan et al. | Apr 2012 | B2 |
8162903 | Reilly et al. | Apr 2012 | B2 |
8162914 | Kraushaar et al. | Apr 2012 | B2 |
8162915 | Brandenburger et al. | Apr 2012 | B2 |
D660423 | Hermle | May 2012 | S |
8172823 | Rondeau et al. | May 2012 | B2 |
8182744 | Mlodzinski et al. | May 2012 | B2 |
8197459 | Jansen et al. | Jun 2012 | B2 |
8206367 | Warren et al. | Jun 2012 | B2 |
D664647 | Becker | Jul 2012 | S |
D664648 | Becker | Jul 2012 | S |
D664649 | Becker | Jul 2012 | S |
8209941 | Osborne et al. | Jul 2012 | B2 |
8216207 | Moy et al. | Jul 2012 | B2 |
8220503 | Tribble et al. | Jul 2012 | B2 |
8220504 | Hartman et al. | Jul 2012 | B2 |
8221382 | Moy et al. | Jul 2012 | B2 |
8225824 | Eliuk et al. | Jul 2012 | B2 |
8225826 | Horppu et al. | Jul 2012 | B2 |
8231567 | Tennican et al. | Jul 2012 | B2 |
8231749 | Dent et al. | Jul 2012 | B2 |
8241265 | Moy et al. | Aug 2012 | B2 |
D667946 | Levesque et al. | Sep 2012 | S |
8267129 | Doherty et al. | Sep 2012 | B2 |
8267912 | Ferris | Sep 2012 | B2 |
8287513 | Ellstrom et al. | Oct 2012 | B2 |
8328082 | Bochenko et al. | Dec 2012 | B1 |
8336587 | Rosenquist et al. | Dec 2012 | B2 |
8356644 | Chong et al. | Jan 2013 | B2 |
8356645 | Chong et al. | Jan 2013 | B2 |
8357137 | Yandell | Jan 2013 | B2 |
8374887 | Alexander | Feb 2013 | B1 |
8381776 | Horppu | Feb 2013 | B2 |
8382696 | Beiriger et al. | Feb 2013 | B2 |
8386070 | Eliuk et al. | Feb 2013 | B2 |
8403905 | Yow | Mar 2013 | B2 |
8409165 | Niedospial, Jr. et al. | Apr 2013 | B2 |
8414554 | Garfield et al. | Apr 2013 | B2 |
8414556 | Garfield et al. | Apr 2013 | B2 |
8425487 | Beiriger et al. | Apr 2013 | B2 |
8430859 | McConnell | Apr 2013 | B2 |
8449521 | Thorne, Jr. et al. | May 2013 | B2 |
D687948 | Levesque et al. | Aug 2013 | S |
8506548 | Okiyama | Aug 2013 | B2 |
8522832 | Lopez et al. | Sep 2013 | B2 |
8551037 | Suchecki et al. | Oct 2013 | B2 |
8562583 | Akerlund et al. | Oct 2013 | B2 |
8562584 | Beiriger et al. | Oct 2013 | B2 |
8567235 | Bojan et al. | Oct 2013 | B2 |
8571708 | Rob et al. | Oct 2013 | B2 |
8602067 | Kuhni et al. | Dec 2013 | B2 |
8608723 | Lev et al. | Dec 2013 | B2 |
8622985 | Ellstrom | Jan 2014 | B2 |
8636720 | Truitt et al. | Jan 2014 | B2 |
8639525 | Levine et al. | Jan 2014 | B2 |
8679075 | Lurvey et al. | Mar 2014 | B2 |
8684994 | Lev et al. | Apr 2014 | B2 |
8701696 | Guala | Apr 2014 | B2 |
8702675 | Imai | Apr 2014 | B2 |
8720496 | Huwiler et al. | May 2014 | B2 |
8721612 | Domkowski et al. | May 2014 | B2 |
8721614 | Takemoto et al. | May 2014 | B2 |
8721627 | Alpert | May 2014 | B2 |
D706415 | Levesque et al. | Jun 2014 | S |
8753325 | Lev et al. | Jun 2014 | B2 |
8763798 | Paul | Jul 2014 | B2 |
8795231 | Chong et al. | Aug 2014 | B2 |
8801689 | Moy et al. | Aug 2014 | B2 |
8821436 | Mosler et al. | Sep 2014 | B2 |
8834444 | Domkowski | Sep 2014 | B2 |
8852147 | Callan et al. | Oct 2014 | B2 |
8864725 | Ranalletta et al. | Oct 2014 | B2 |
8864737 | Hasegawa et al. | Oct 2014 | B2 |
8870832 | Raday et al. | Oct 2014 | B2 |
8882739 | Domkowski et al. | Nov 2014 | B2 |
8894627 | Garfield et al. | Nov 2014 | B2 |
8911421 | Domkowski et al. | Dec 2014 | B2 |
D721803 | Dubach | Jan 2015 | S |
8926554 | Okuda et al. | Jan 2015 | B2 |
8958112 | Matsui et al. | Feb 2015 | B2 |
D724198 | Oostman et al. | Mar 2015 | S |
8973622 | Lopez et al. | Mar 2015 | B2 |
8979792 | Lev et al. | Mar 2015 | B2 |
9033006 | Perazzo et al. | May 2015 | B2 |
9043019 | Eliuk et al. | May 2015 | B2 |
9056164 | Tate et al. | Jun 2015 | B2 |
9057363 | Capone | Jun 2015 | B2 |
9057370 | Mundt et al. | Jun 2015 | B2 |
9060923 | Hossainy | Jun 2015 | B2 |
9061130 | Truitt et al. | Jun 2015 | B2 |
9076115 | Utech et al. | Jul 2015 | B2 |
9079686 | Domkowski et al. | Jul 2015 | B2 |
9089474 | Cederschiöld | Jul 2015 | B2 |
9089647 | Haenggi et al. | Jul 2015 | B2 |
9101717 | Mansour et al. | Aug 2015 | B2 |
9114242 | Fangrow, Jr. et al. | Aug 2015 | B2 |
9132062 | Fangrow | Sep 2015 | B2 |
9132063 | Lev et al. | Sep 2015 | B2 |
9139316 | Husnu et al. | Sep 2015 | B2 |
9144646 | Barron, III et al. | Sep 2015 | B2 |
9149576 | Bullington et al. | Oct 2015 | B2 |
9198832 | Moy et al. | Dec 2015 | B2 |
9211231 | Mansour et al. | Dec 2015 | B2 |
9212762 | Duncan | Dec 2015 | B2 |
9220661 | Garfield et al. | Dec 2015 | B2 |
D747472 | Bradley et al. | Jan 2016 | S |
9227048 | Frattini | Jan 2016 | B2 |
9241875 | Davis et al. | Jan 2016 | B2 |
9242039 | Valk et al. | Jan 2016 | B2 |
9270890 | Okuma et al. | Feb 2016 | B2 |
9345640 | Mosler | May 2016 | B2 |
9345641 | Krause et al. | May 2016 | B2 |
9345643 | Okiyama | May 2016 | B2 |
9381135 | Reynolds et al. | Jul 2016 | B2 |
9381137 | Garfield et al. | Jul 2016 | B2 |
9382021 | Tribble et al. | Jul 2016 | B2 |
9402786 | Petrone | Aug 2016 | B2 |
9408966 | Kamen | Aug 2016 | B2 |
9466088 | Perazzo et al. | Oct 2016 | B2 |
9474690 | Ranalletta et al. | Oct 2016 | B2 |
9475019 | Kaucky et al. | Oct 2016 | B2 |
9481477 | Kjar | Nov 2016 | B2 |
D774192 | Fuchs | Dec 2016 | S |
D775325 | Larson et al. | Dec 2016 | S |
9511989 | Lopez et al. | Dec 2016 | B2 |
9561893 | Root et al. | Feb 2017 | B2 |
9579255 | Eliuk et al. | Feb 2017 | B2 |
9615997 | Fangrow | Apr 2017 | B2 |
9629955 | Bresina et al. | Apr 2017 | B2 |
9744102 | Kubo | Aug 2017 | B2 |
9770388 | Noike et al. | Sep 2017 | B2 |
9775778 | Qiu et al. | Oct 2017 | B2 |
9801787 | Py | Oct 2017 | B2 |
9802171 | Konrad, Jr. et al. | Oct 2017 | B2 |
9802172 | Konrad, Jr. et al. | Oct 2017 | B2 |
D803396 | Oberkircher et al. | Nov 2017 | S |
9827163 | Lopez et al. | Nov 2017 | B2 |
9827680 | Davey et al. | Nov 2017 | B2 |
D804651 | Loonan | Dec 2017 | S |
9833605 | Sanders et al. | Dec 2017 | B2 |
9849236 | Hachey et al. | Dec 2017 | B2 |
9883987 | Lopez et al. | Feb 2018 | B2 |
9930297 | Alexander et al. | Mar 2018 | B2 |
9931276 | Lopez et al. | Apr 2018 | B2 |
D819414 | Solomon | Jun 2018 | S |
10106278 | Chang et al. | Oct 2018 | B2 |
10143985 | Brown et al. | Dec 2018 | B2 |
D837983 | Fangrow | Jan 2019 | S |
10181186 | Kriheli et al. | Jan 2019 | B2 |
10188849 | Fangrow | Jan 2019 | B2 |
10189616 | Kraft | Jan 2019 | B2 |
D846146 | Amos et al. | Apr 2019 | S |
10259608 | Fianchini et al. | Apr 2019 | B2 |
D851745 | Shauver et al. | Jun 2019 | S |
10307338 | Hellenbrand | Jun 2019 | B2 |
10314764 | Lopez et al. | Jun 2019 | B2 |
10314765 | Lopez et al. | Jun 2019 | B2 |
10315174 | Konrad, Jr. et al. | Jun 2019 | B2 |
10327987 | Bochenko et al. | Jun 2019 | B1 |
10327988 | Tribble et al. | Jun 2019 | B2 |
10336477 | Perazzo et al. | Jul 2019 | B2 |
10417758 | Alexander | Sep 2019 | B1 |
10420927 | Fangrow | Sep 2019 | B2 |
10494126 | Joplin | Dec 2019 | B2 |
10503873 | Prince et al. | Dec 2019 | B2 |
10512885 | Janders et al. | Dec 2019 | B2 |
D874644 | Shauver et al. | Feb 2020 | S |
10554937 | Alexander et al. | Feb 2020 | B2 |
10556062 | Simpson et al. | Feb 2020 | B2 |
10576211 | Hang et al. | Mar 2020 | B2 |
D887577 | Shor et al. | Jun 2020 | S |
10791975 | Wilkinson et al. | Oct 2020 | B2 |
D905228 | Shauver et al. | Dec 2020 | S |
11007119 | Lopez et al. | May 2021 | B2 |
11020541 | Fangrow et al. | Jun 2021 | B2 |
11033459 | Ariagno et al. | Jun 2021 | B2 |
11135416 | Fangrow | Oct 2021 | B2 |
D943732 | Shauver et al. | Feb 2022 | S |
D948044 | Fangrow | Apr 2022 | S |
11439570 | Lopez et al. | Sep 2022 | B2 |
11439571 | Lopez et al. | Sep 2022 | B2 |
11541171 | Hachey et al. | Jan 2023 | B2 |
11583637 | Fangrow et al. | Feb 2023 | B2 |
20020017328 | Loo | Feb 2002 | A1 |
20020064880 | Merten et al. | May 2002 | A1 |
20020085952 | Ellingboe et al. | Jul 2002 | A1 |
20020095121 | Norton et al. | Jul 2002 | A1 |
20020179544 | Johnson et al. | Dec 2002 | A1 |
20020189712 | Safabash | Dec 2002 | A1 |
20030023226 | Lopez | Jan 2003 | A1 |
20030153895 | Leinsing | Aug 2003 | A1 |
20030188897 | Ludi et al. | Oct 2003 | A1 |
20030236500 | Scheu | Dec 2003 | A1 |
20040031756 | Suzuki et al. | Feb 2004 | A1 |
20040035743 | Tighe et al. | Feb 2004 | A1 |
20040073161 | Tachibana | Apr 2004 | A1 |
20040087888 | Digianfilippo et al. | May 2004 | A1 |
20040116891 | Curutcharry | Jun 2004 | A1 |
20040118477 | Desmond | Jun 2004 | A1 |
20040138627 | Forrest | Jul 2004 | A1 |
20040225274 | Jansen et al. | Nov 2004 | A1 |
20050033260 | Kubo et al. | Feb 2005 | A1 |
20050059952 | Giuliano et al. | Mar 2005 | A1 |
20050096627 | Howard | May 2005 | A1 |
20050131357 | Denton et al. | Jun 2005 | A1 |
20050230575 | Zelenski et al. | Oct 2005 | A1 |
20050252572 | Khan et al. | Nov 2005 | A1 |
20050252574 | Khan et al. | Nov 2005 | A1 |
20050267413 | Wang et al. | Dec 2005 | A1 |
20060048844 | Merrill | Mar 2006 | A1 |
20060064053 | Bollish et al. | Mar 2006 | A1 |
20060169348 | Yigal | Aug 2006 | A1 |
20060259195 | Eliuk et al. | Nov 2006 | A1 |
20070007478 | Leinsing et al. | Jan 2007 | A1 |
20070017583 | Fangrow | Jan 2007 | A1 |
20070088252 | Pestotnik et al. | Apr 2007 | A1 |
20070088313 | Zinger et al. | Apr 2007 | A1 |
20070106244 | Mosler et al. | May 2007 | A1 |
20070151984 | Baker et al. | Jul 2007 | A1 |
20070169836 | Djurle et al. | Jul 2007 | A1 |
20070244447 | Capitaine et al. | Oct 2007 | A1 |
20070287953 | Ziv et al. | Dec 2007 | A1 |
20080059228 | Bossi et al. | Mar 2008 | A1 |
20080065006 | Roger et al. | Mar 2008 | A1 |
20080077116 | Dailey et al. | Mar 2008 | A1 |
20080086088 | Malcolm | Apr 2008 | A1 |
20080086094 | Peters | Apr 2008 | A1 |
20080114328 | Doherty et al. | May 2008 | A1 |
20080125897 | DiGianfilippo et al. | May 2008 | A1 |
20080169043 | Osborne et al. | Jul 2008 | A1 |
20080169044 | Osborne et al. | Jul 2008 | A1 |
20080172024 | Yow | Jul 2008 | A1 |
20080177222 | Roger | Jul 2008 | A1 |
20080195416 | Tribble et al. | Aug 2008 | A1 |
20080199353 | Mlodzinski et al. | Aug 2008 | A1 |
20080269680 | Ibranyan et al. | Oct 2008 | A1 |
20080287920 | Fangrow et al. | Nov 2008 | A1 |
20090012449 | Lee et al. | Jan 2009 | A1 |
20090050216 | Trocki et al. | Feb 2009 | A1 |
20090067973 | Eliuk et al. | Mar 2009 | A1 |
20090069743 | Krishnamoorthy et al. | Mar 2009 | A1 |
20090082649 | Muller et al. | Mar 2009 | A1 |
20090088687 | Yardimci et al. | Apr 2009 | A1 |
20090099547 | Radmer | Apr 2009 | A1 |
20090101576 | Rohde et al. | Apr 2009 | A1 |
20090126825 | Eliuk et al. | May 2009 | A1 |
20090145509 | Baker et al. | Jun 2009 | A1 |
20090149743 | Barron et al. | Jun 2009 | A1 |
20090154764 | Khan et al. | Jun 2009 | A1 |
20090163860 | Patrick et al. | Jun 2009 | A1 |
20090177149 | Childers et al. | Jul 2009 | A1 |
20090198215 | Chong et al. | Aug 2009 | A1 |
20090223592 | Procyshyn et al. | Sep 2009 | A1 |
20090223990 | Bailey et al. | Sep 2009 | A1 |
20090254031 | Lee | Oct 2009 | A1 |
20090270832 | Vancaillie et al. | Oct 2009 | A1 |
20090306621 | Thome, Jr. et al. | Dec 2009 | A1 |
20100024904 | Hoffman et al. | Feb 2010 | A1 |
20100049157 | Fangrow | Feb 2010 | A1 |
20100121246 | Peters et al. | May 2010 | A1 |
20100245056 | Braun et al. | Sep 2010 | A1 |
20100276034 | Gonnelli et al. | Nov 2010 | A1 |
20100280430 | Caleffi et al. | Nov 2010 | A1 |
20100286606 | Ding | Nov 2010 | A1 |
20110004143 | Beiriger et al. | Jan 2011 | A1 |
20110004187 | Beiriger | Jan 2011 | A1 |
20110067781 | Osborne | Mar 2011 | A1 |
20110087164 | Mosler et al. | Apr 2011 | A1 |
20110152757 | Beck et al. | Jun 2011 | A1 |
20110175347 | Okiyama | Jul 2011 | A1 |
20110178493 | Okiyama | Jul 2011 | A1 |
20110196304 | Kramer et al. | Aug 2011 | A1 |
20110204144 | Waugh et al. | Aug 2011 | A1 |
20110229517 | Strahlendorf et al. | Sep 2011 | A1 |
20110276031 | Hoang et al. | Nov 2011 | A1 |
20110305545 | Davis et al. | Dec 2011 | A1 |
20120067429 | Mosler et al. | Mar 2012 | A1 |
20120109077 | Ryan | May 2012 | A1 |
20120123298 | Mendels et al. | May 2012 | A1 |
20120157914 | Stroup | Jun 2012 | A1 |
20120302986 | Brem et al. | Nov 2012 | A1 |
20130006214 | Garfield et al. | Jan 2013 | A1 |
20130018356 | Prince et al. | Jan 2013 | A1 |
20130053815 | Mucientes et al. | Feb 2013 | A1 |
20130085439 | Sansoucy et al. | Apr 2013 | A1 |
20130102772 | Eshima et al. | Apr 2013 | A1 |
20130211332 | Beiriger et al. | Aug 2013 | A1 |
20130218121 | Waller et al. | Aug 2013 | A1 |
20130220484 | De Marco | Aug 2013 | A1 |
20130292004 | Ducret et al. | Nov 2013 | A1 |
20140020790 | Yuyama et al. | Jan 2014 | A1 |
20140039392 | Geipel et al. | Feb 2014 | A1 |
20140124087 | Anderson et al. | May 2014 | A1 |
20140135732 | Spronken et al. | May 2014 | A1 |
20140136229 | Levine et al. | May 2014 | A1 |
20140150925 | Sjogren et al. | Jun 2014 | A1 |
20140261727 | Mansour et al. | Sep 2014 | A1 |
20140261860 | Heath | Sep 2014 | A1 |
20140261877 | Ivosevic et al. | Sep 2014 | A1 |
20140263614 | Keefe et al. | Sep 2014 | A1 |
20140276386 | Mansour et al. | Sep 2014 | A1 |
20140276649 | Ivosevic et al. | Sep 2014 | A1 |
20140323970 | Duncan | Oct 2014 | A1 |
20140350949 | Utech et al. | Nov 2014 | A1 |
20150000784 | Jamaledine | Jan 2015 | A1 |
20150008664 | Tachizaki | Jan 2015 | A1 |
20150025453 | Ledford et al. | Jan 2015 | A1 |
20150040987 | Reichert et al. | Feb 2015 | A1 |
20150040988 | Reichert et al. | Feb 2015 | A1 |
20150041531 | Vavala et al. | Feb 2015 | A1 |
20150045772 | Reichert et al. | Feb 2015 | A1 |
20150082746 | Ivosevic et al. | Mar 2015 | A1 |
20150101707 | Ranalletta et al. | Apr 2015 | A1 |
20150119820 | Kanamoto | Apr 2015 | A1 |
20150123398 | Sanders et al. | May 2015 | A1 |
20150126958 | Sanders et al. | May 2015 | A1 |
20150133879 | Kanamoto et al. | May 2015 | A1 |
20150151041 | Yodfat et al. | Jun 2015 | A1 |
20150157536 | Qiu et al. | Jun 2015 | A1 |
20150161354 | Blomquist | Jun 2015 | A1 |
20150202382 | Juretich et al. | Jul 2015 | A1 |
20150202383 | Juretich et al. | Jul 2015 | A1 |
20150202384 | Juretich et al. | Jul 2015 | A1 |
20150202385 | Juretich et al. | Jul 2015 | A1 |
20150209230 | Lev et al. | Jul 2015 | A1 |
20150209233 | Fukuoka | Jul 2015 | A1 |
20150209495 | Biset et al. | Jul 2015 | A1 |
20150209510 | Burkholz et al. | Jul 2015 | A1 |
20150250680 | Browka et al. | Sep 2015 | A1 |
20150250681 | Lev et al. | Sep 2015 | A1 |
20150257977 | Bochenko et al. | Sep 2015 | A1 |
20150265500 | Russo et al. | Sep 2015 | A1 |
20150297451 | Mariei et al. | Oct 2015 | A1 |
20150297453 | Kim et al. | Oct 2015 | A1 |
20150297454 | Sanders et al. | Oct 2015 | A1 |
20150297456 | Mariei et al. | Oct 2015 | A1 |
20150297459 | Sanders et al. | Oct 2015 | A1 |
20150297460 | Mansour et al. | Oct 2015 | A1 |
20150297839 | Sanders et al. | Oct 2015 | A1 |
20150297881 | Sanders et al. | Oct 2015 | A1 |
20150314066 | Shimizu | Nov 2015 | A1 |
20150320992 | Bonnet et al. | Nov 2015 | A1 |
20150346013 | Feng et al. | Dec 2015 | A1 |
20150359709 | Kriheli et al. | Dec 2015 | A1 |
20150366758 | Noguchi et al. | Dec 2015 | A1 |
20160000653 | Kramer | Jan 2016 | A1 |
20160001003 | Perazzo et al. | Jan 2016 | A1 |
20160038373 | Ohlin | Feb 2016 | A1 |
20160038374 | Merhold et al. | Feb 2016 | A1 |
20160051446 | Lev et al. | Feb 2016 | A1 |
20160058666 | Strahlendorf et al. | Mar 2016 | A1 |
20160058667 | Kriheli | Mar 2016 | A1 |
20160081878 | Marks et al. | Mar 2016 | A1 |
20160101020 | Guala | Apr 2016 | A1 |
20160114922 | Bonhora et al. | Apr 2016 | A1 |
20160136051 | Lavi | May 2016 | A1 |
20160136412 | McKinnon et al. | May 2016 | A1 |
20160140315 | Diaz et al. | May 2016 | A1 |
20160158104 | Ali et al. | Jun 2016 | A1 |
20160158437 | Biasi et al. | Jun 2016 | A1 |
20160206511 | Garfield et al. | Jul 2016 | A1 |
20160213861 | Whitaker et al. | Jul 2016 | A1 |
20160213862 | Whitaker et al. | Jul 2016 | A1 |
20160256632 | Fangrow | Sep 2016 | A1 |
20160262981 | Carrez et al. | Sep 2016 | A1 |
20160310362 | Lane et al. | Oct 2016 | A1 |
20160331893 | Yeh et al. | Nov 2016 | A1 |
20160354281 | O'Neill et al. | Dec 2016 | A1 |
20170007501 | Schuldt-Lieb et al. | Jan 2017 | A1 |
20170020428 | Rogers et al. | Jan 2017 | A1 |
20170081168 | Seay et al. | Mar 2017 | A1 |
20170128666 | Davis | May 2017 | A1 |
20170129763 | Fangrow, Jr. | May 2017 | A1 |
20170146381 | Eckel et al. | May 2017 | A1 |
20170165435 | Green | Jun 2017 | A1 |
20170165436 | Haddad et al. | Jun 2017 | A1 |
20170255760 | Lee et al. | Sep 2017 | A1 |
20170312716 | Konrad, Jr. et al. | Nov 2017 | A1 |
20170354571 | David et al. | Dec 2017 | A1 |
20180028403 | Fangrow | Feb 2018 | A1 |
20180043323 | Janders et al. | Feb 2018 | A1 |
20180055738 | Chen et al. | Mar 2018 | A1 |
20180065097 | Konrad, Jr. et al. | Mar 2018 | A1 |
20180133667 | Lee et al. | May 2018 | A1 |
20180161244 | Lopez | Jun 2018 | A1 |
20180168930 | Tunesi | Jun 2018 | A1 |
20180168935 | Chen et al. | Jun 2018 | A1 |
20180177940 | Hachey et al. | Jun 2018 | A1 |
20180194505 | Amano et al. | Jul 2018 | A1 |
20180207063 | Lopez | Jul 2018 | A1 |
20180232497 | Hoffman et al. | Aug 2018 | A1 |
20180263850 | Schneider et al. | Sep 2018 | A1 |
20180344572 | Zollinger et al. | Dec 2018 | A1 |
20180353381 | Pak et al. | Dec 2018 | A1 |
20180353382 | Zollinger et al. | Dec 2018 | A1 |
20180354662 | Feith et al. | Dec 2018 | A1 |
20180357476 | Klumph | Dec 2018 | A1 |
20180360689 | Zollinger et al. | Dec 2018 | A1 |
20190019576 | DeCiccio et al. | Jan 2019 | A1 |
20190021947 | Bomgaars et al. | Jan 2019 | A1 |
20190056419 | Procyshyn et al. | Feb 2019 | A1 |
20190070405 | Fangrow | Mar 2019 | A1 |
20190091639 | Brown et al. | Mar 2019 | A1 |
20190105619 | Wilson et al. | Apr 2019 | A1 |
20190151569 | Fangrow et al. | May 2019 | A1 |
20190152663 | Kraft | May 2019 | A1 |
20190163876 | Remme et al. | May 2019 | A1 |
20190170663 | Pirkle et al. | Jun 2019 | A1 |
20190216683 | Yaegashi | Jul 2019 | A1 |
20190244466 | Berg et al. | Aug 2019 | A1 |
20190247280 | Hellenbrand | Aug 2019 | A1 |
20190262790 | Konrad, Jr. et al. | Aug 2019 | A1 |
20190275243 | Deck et al. | Sep 2019 | A1 |
20190307643 | Tribble et al. | Oct 2019 | A1 |
20190388302 | Schobel et al. | Dec 2019 | A1 |
20200016037 | Oda et al. | Jan 2020 | A1 |
20200066389 | Prince et al. | Feb 2020 | A1 |
20200093699 | Oda et al. | Mar 2020 | A1 |
20200113784 | Lopez et al. | Apr 2020 | A1 |
20200113785 | Lopez | Apr 2020 | A1 |
20200206492 | Fangrow | Jul 2020 | A1 |
20200289370 | Lopez | Sep 2020 | A1 |
20200297581 | Lopez et al. | Sep 2020 | A1 |
20210002008 | Min et al. | Jan 2021 | A1 |
20210121363 | Oda et al. | Apr 2021 | A1 |
20210259921 | Lopez | Aug 2021 | A1 |
20210308012 | Tagliamento et al. | Oct 2021 | A1 |
20220008711 | Fangrow | Jan 2022 | A1 |
20220054766 | Fangrow et al. | Feb 2022 | A1 |
20220379697 | Lopez | Dec 2022 | A1 |
Number | Date | Country |
---|---|---|
1707379 | Dec 2005 | CN |
101244297 | Aug 2008 | CN |
106860003 | Jun 2017 | CN |
107198658 | Sep 2017 | CN |
108210332 | Jun 2018 | CN |
202 16 791 | Feb 2003 | DE |
20 2004 014 868 | Nov 2004 | DE |
0 521 460 | Sep 1995 | EP |
0 974 330 | Jan 2000 | EP |
1 533 597 | May 2005 | EP |
1 563 819 | Aug 2005 | EP |
1 997 471 | Dec 2008 | EP |
3 375 427 | Sep 2018 | EP |
S55-156750 | Nov 1980 | JP |
55-173339 | Dec 1980 | JP |
56-95247 | Aug 1981 | JP |
62-189072 | Aug 1987 | JP |
06-343706 | Dec 1994 | JP |
10-118158 | May 1998 | JP |
2001-190689 | Jul 2001 | JP |
2002-238979 | Aug 2002 | JP |
2002-355318 | Dec 2002 | JP |
2003-144546 | May 2003 | JP |
2003-199823 | Jul 2003 | JP |
2003-225305 | Aug 2003 | JP |
2004-049497 | Feb 2004 | JP |
2007-14618 | Jan 2007 | JP |
2007-215775 | Aug 2007 | JP |
WO 199714493 | Apr 1997 | KR |
2011-0019800 | Mar 2011 | KR |
10-1574194 | Dec 2015 | KR |
WO 199823353 | Jun 1998 | WO |
WO 199919012 | Apr 1999 | WO |
WO 199963547 | Dec 1999 | WO |
WO 200041751 | Jul 2000 | WO |
WO 200103757 | Jan 2001 | WO |
WO 2001039874 | Jun 2001 | WO |
WO 200204065 | Jan 2002 | WO |
WO 2002013890 | Feb 2002 | WO |
WO 2005041846 | May 2005 | WO |
WO 2005110007 | Nov 2005 | WO |
WO 2005123162 | Dec 2005 | WO |
WO 2007033013 | Mar 2007 | WO |
WO 2007061424 | May 2007 | WO |
WO 2007062315 | May 2007 | WO |
WO 2070793050 | Jul 2007 | WO |
WO 2007148708 | Dec 2007 | WO |
WO 2008051998 | May 2008 | WO |
WO 2008052140 | May 2008 | WO |
WO 2008128074 | Oct 2008 | WO |
WO 2008144447 | Nov 2008 | WO |
WO 2009060419 | May 2009 | WO |
WO 2009130147 | Oct 2009 | WO |
WO 2009140511 | Nov 2009 | WO |
WO 2010111548 | Sep 2010 | WO |
WO 2011002853 | Jan 2011 | WO |
WO 2011012313 | Feb 2011 | WO |
WO 2011014525 | Feb 2011 | WO |
WO 2011058545 | May 2011 | WO |
WO 2011058548 | May 2011 | WO |
WO 2011091542 | Aug 2011 | WO |
WO 2011091643 | Aug 2011 | WO |
WO 2011104711 | Sep 2011 | WO |
WO 2011104712 | Sep 2011 | WO |
WO 2011150037 | Dec 2011 | WO |
WO 2012119225 | Sep 2012 | WO |
WO 2013096911 | Jun 2013 | WO |
WO 2014122643 | Aug 2014 | WO |
WO 2014126473 | Aug 2014 | WO |
WO 2014177347 | Nov 2014 | WO |
WO 2014181320 | Nov 2014 | WO |
WO 2015029020 | Mar 2015 | WO |
WO 2015077184 | May 2015 | WO |
WO 2015077466 | May 2015 | WO |
WO 2015122921 | Aug 2015 | WO |
WO 2016010909 | Jan 2016 | WO |
WO 2017096072 | Jun 2017 | WO |
WO 2018009996 | Jan 2018 | WO |
WO 2018022640 | Feb 2018 | WO |
WO 2019018195 | Jan 2019 | WO |
WO 2021201884 | Oct 2021 | WO |
Entry |
---|
U.S. Appl. No. 29/571,547, filed Jul. 19, 2016, Shauver et al. |
U.S. Appl. No. 29/586,575, filed Dec. 5, 2016, Fangrow |
Abbott “Plum A”, System Operating Manual (For use with List 11971-04) in 85 pages, May 2001. |
Autoyec 50, from KRZ, Dec. 6, 2007. |
B. Braun Medical Inc. Two-Bag Irrigation Set, Two-Non-vented Spikes, dated Jul. 2012, in 1 page. |
Baxa Corp. v. McGaw Inc. 981 F. Supp. 1348 (1997), Memorandum Opinion and Order, 14 pages. |
BioExpert International Inc., Company overview, credential for Rabih Jamaleddine, Nabil Kereknawi, and Danica Robillard Corso, copyright 2010 BioExpert International Inc. in 3 pages [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://bioexpert.ca.about.html. |
Burrows, et al., “Intravenous (IV) Fluidmaker IV. A Disposable Device for Preparation of Sterile Water for Injection In a Field Setting,” Fort Detrick, US Army Biomedical Research & Development Laboratory, Sep. 1991, https://apps.dtc.mil/dtic/tr/fulltest/u2/a247385.pdf. |
Canadian Office Action, re CA Application No. 2,768,985, dated Jun. 27, 2016. |
Cato (Computer Aided Therapy For Oncology)—Reference Manual—Vienna, May 2005, 255 pgs. |
Clearlink Needleless IV Access System, dated Aug. 2007, in 2 pages. |
CytoCare, by Health Robotics, Brochure, Date Unknown, downloaded on May 25, 2012 from http://www.health-robotics.com/smartedit/downloads/en/cytocare7.pdf, 6 pages. |
Exacta-Mix 2400, from Baxa, which appears to have a date of 2007, 2 pages. |
Flickinger, Bruce, “Misperceptions Cloud the Issue of Sterile Drug Compounding,” Jun. 2007. |
Fox, Brent I., “Pharmacy Automation and Technology: Automated Intravenous Preparation: Robots for the Pharmacy,” Hospital Pharmacy, vol. 44, Mar. 2009, pp. 255-257. |
Grifols International, S.A., “PHOCUS Rx, Remote IV Compounding Validation” product brochure and “Product Description Sheet” in 13 pages [Publication Date unknown but may be May 29, 2013]. |
Healthmark, “Hospital Medication Preparation, Packaging and Dispensing”in 1 page [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://www.healthmark.ca/2-en-Hospital-Medication-Preparation-Packaging-and-Dispensing.html. |
Healthmark, “Hospital Medication Preparation, Packaging and Dispensing,” Chemo Drug Preparation/Administration in 2 pages [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://www.healthmark.ca/2-36-88-Chemo-Drug-Preparation-Administration_en.html. |
Healthmark, “Hospital Medication Preparation, Packaging and Dispensing,” Chemosphere, Sterile Chemo Compounding (Isolator) in 1 page [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://www.healthmark.ca/2-36-10-ChemoSphere_en.html?ProductID=244. |
Healthmark, “Hospital Medication Preparation, Packaging and Dispensing,” Oncology Preparation and Administration in 1 page [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://www.healthmark.ca/2-36-10-COMPANY-PROFILEHospital-en.html. |
Healthmark, “Hospital Medication Preparation, Packaging and Dispensing,”Phocus-RX (Camera Verification System), Remote Rx Checking of admixtures in 2 pages [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://www.healthmark.ca/2-36-10-PHOCUS-Rx-Camera-Verification-System-_en.html?ProductID=229. |
Healthmark, “New Product Items” in 1 page [retrieved on Jan. 6, 2015; Publication Date Unknown]; accessed on the world wide web at http://www.healthmark.ca/home.html. |
Healthmark, “Introducing the Precifill Dispensing Pump” product brochure in 2 pages [Publication Date Unknown]. |
Integra Brochure, from Eurospital, Brochure acquired in Mar. 2012. |
International Invitation to Pay Additional Fees (with cited art), re PCT Application No. PCT/US17/43761, dated Sep. 21, 2017. |
International Preliminary Report on Patentability, re PCT Appliation No. PCT/US 17/43761, issued Jan. 29, 2019. |
International Search Report and Written Opinion, re PCT Application No. PCT/US 17/43761, dated Nov. 17, 2017. |
ISO/Tech Design, QC, Canada, “Chemosphere,” product brochure, in 2 pages [Publication Date Unknown]. |
Neo Care Medical Products; Product Catalog, dated Jun. 2008, in 38 pages. |
Pinnacle TPN Management System, from B Braun, downloaded May 5, 2009 from http://www.bbraunusa.com/index. cfm?uuid=7386ADF065B05CD0D22AF700339AA4092, 1 page. |
“Precifill,” Trademark search (TESS) in 1 page, [retrieved on Jan. 6, 2015; Application Filing Date of Sep. 30, 2011]; accessed on the world wide web at http://trnsearch.uspto.gov/bin/showfield?f=doc&state=4807:gz67gx.3.1. |
Product detail “NAMIC® Closed Fluid Systems” from Navilyst Medical, downloaded on May 11, 2010 from http://www.navilystmedical.com/Products/index.cfm/19, 2 pages. |
Product detail for “RapidFill™ Automated Syringe Filler,” from Baxa, downloaded on Mar. 31, 2010 from http://www.baxa.com/PharmacyProducts/AutomatedFillingSystems/ProductDetail/?id=B1, 2 pages. |
Product detail for “Summit Medical DirectFlow” micro infusion extension set from Summit Medical Technologies, downloaded on May 10, 2010 from http://summitmedtech.com/p6line.php, 1 page. |
Riva, downloaded in Apr. 2009 from http://www.rivasystem.com, 6 pages. |
SmartSite Safety Disposable, with copyright notice dated 2004. |
Smith, “Lifesaving Cancer Drugs May Put Workers' Lives at Risk,” downloaded on Jul. 12, 2010 from http://www.msnbc.msn.com/id/38114586/ns/health-cancer, 7 pages. |
Spiros—Closed Male Connector, published Jan. 22, 2008. |
Technical Data sheet for Analog Amplifiers Type VA, models V8-C and V8-D, STM Sensors dated Dec. 2007, 4 pages. |
Technical Data sheet for Through Beam Sensors Type G2, 1480 nm, STM Sensors dated Dec. 2009, 2 pages. |
Technical Data sheet for Through Beam Sensors Type G2, 645 nm, STM Sensors dated Sep. 2008, 2 pages. |
User Guide for medOC 1xx Basic, Neo Care Medical Products GmbH, Version Jun. 2008, 23 pages. |
User Manual for medOC 3xx /6xx /8xx, Neo Care Medical Products GmbH, Version May 2008, 44 pages. |
Number | Date | Country | |
---|---|---|---|
20240033447 A1 | Feb 2024 | US |
Number | Date | Country | |
---|---|---|---|
62366509 | Jul 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17240021 | Apr 2021 | US |
Child | 18170838 | US | |
Parent | 16255710 | Jan 2019 | US |
Child | 17240021 | US | |
Parent | PCT/US2017/043761 | Jul 2017 | US |
Child | 16255710 | US |